ipilimumab,nivolumab
bms
['niche-2']
#esmo22 highlights: talks about the incredible results from the niche-2 trial #coloncancer #immunotherapy 
The company is a leading provider of an AI-powered precision oncology platform transforming biomarker discovery and treatment decisions.